Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Patisiran is a transthyretin-directed small interfering RNA used to treat polyneuropathy of hereditary transthyretin-mediated amyloidosis. It is marketed as Onpattro which is formulated as patisiran within a liposome envelope for better delivery to the liver, where transthyretin is produced.
- Mechanism
- Curator reviewed
Patisirant is a double-stranded short interfering RNA (siRNA) targeting mRNA encoding both wild-type and mutant transthyretin. Patisiran enters the cell an is processed by the Dicer enzyme. This processing involved cleaving overhanging nucleotides on the edges of the RNA. Once processed the siRNA can bind to the RNA-induced silencing complex (RISC). RISC separates the strands of the RNA sequence. One strand is released and one remains bound. The bound strand then acts as a targeting sequence for a complimentary mRNA sequence. In this case, the bound strand of patisiran binds to the complimentary transthyretin mRNA and aligns the RISC complex with it. The transthyretin mRNA is then cleaved and rendered non-functional. One targeting sequence may be used to destroy many copies of complimentary mRNA.
- Primary indication
- Patisirant is indicated for the treatment of hereditary transthyretin-mediated amyloidosis in adults.Curator reviewed · 1 structured indication
- First approval
- Canada, 2019 · United States, 2018 · European Union, 2021
- Code names
- ALN-18328 · ALN-TTR02
- Brand names
- Onpattro
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Patisiran, and which of those have an active Phase 3 trial?